Evidence map›Paper›PMID 34988453›Full record

ArticleNeuro-oncology advances

Extent of

Michael T C Poon, Shivank Keni, Vineeth Vimalan, Chak Ip, Colin Smith, Sara Erridge, Christopher J Weir, Paul M Brennan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michael T C PoonCentre for Medical Informatics, Usher Institute, University of Edinburgh, UK.ORCID https://orcid.org/0000-0002-0053-2184
Shivank KeniEdinburgh Medical School, University of Edinburgh, UK.
Vineeth VimalanDepartment of Clinical Neuroscience, Royal Infirmary of Edinburgh, NHS Lothian, UK.
Chak IpRoyal Infirmary of Edinburgh, NHS Lothian, UK.
Colin SmithCentre for Comparative Pathology, University of Edinburgh, UK.
Sara ErridgeClinical Oncology, Western General Hospital, NHS Lothian, UK.
Christopher J WeirEdinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, UK.
Paul M BrennanDepartment of Clinical Neuroscience, Royal Infirmary of Edinburgh, NHS Lothian, UK.
NHS Lothian · GBUniversity of Edinburgh · GB

Funding

Cancer Research UK 27589
6 · The paper itself

Abstract

background

methodsWe included consecutive glioblastoma patients aged ≥16 years diagnosed (April 2012-May 2020) at a neuro-oncology center. All patients had quantitative

resultsThere were 414 patients. Optimal cut-off point using Youden index was 25.9%

conclusionsQuantitative

Indexed as

effect modificationGBMO-6 methylguanine-DNA methyltransferaseTemodal

Identifiers

PMID34988453
PMCPMC8704383
OpenAlexW3215045803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.